FindTrial
Sign In

To assess the bacterial growth in small intestine in patients with irritable bowel syndrome

Small intestinal bacterial overgrowth in patients with Irritable bowel syndrome and the effect of Rifaximin therapy on global symptom score - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/10/058513
Enrollment
71
Registered
2023-10-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K58- Irritable bowel syndrome

Interventions

Intervention1: NA: NA Control Intervention1: NA: NA

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed to have Irritable bowel syndrome according to ROME IV criteria.

Exclusion criteria

Exclusion criteria: Patients who are already on antibiotic therapy History of prior gastric surgery/ vagotomy History of treatment with any antibiotics during the one month preceding the test Patients diagnosed with other organ failures (heart failure class IV, chronic obstructive lung diseases, chronic kidney disease, HIV, unrelated treatment history with drugs known to interfere with gastrointestinal motility (such as anticholinergics and antidepressants)to present ailment which can influence the outcome of this study Pregnancy

Design outcomes

Primary

MeasureTime frame
To look for the prevalence of SIBO in patients with IBS with a glucose hydrogen breath test.Timepoint: 1 year—

Secondary

MeasureTime frame
To look for a change in symptoms of IBS after 2 weeks of Antibiotic therapy based on IBS Severity score.Timepoint: 1 year—

Countries

India

Contacts

Public ContactDr Anand Kumar

Manipal Academy of Higher Education

shiran.shetty@manipal.edu8861920517

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026